about
Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment optionsAssessing cardiovascular risk in hepatitis C: An unmet needReview article: HCV genotype 3 – the new treatment challengeImaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver diseaseNew technologies - new insights into the pathogenesis of hepatic encephalopathy.Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should doMetformin inhibits glutaminase activity and protects against hepatic encephalopathyPrediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver.Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection.Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.Role of assessing liver fibrosis in management of chronic hepatitis C virus infection.Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.FibroGENE: A gene-based model for staging liver fibrosis.Low phase angle is associated with the development of hepatic encephalopathy in patients with cirrhosis.Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.Pharmacogenetics of ribavirin-induced anemia in hepatitis C.Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis.Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection.Minimal hepatic encephalopathy and critical flicker frequency are associated with survival of patients with cirrhosis.Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment.[Myelotoxicity due to interaction between azathioprine and allopurinol in a patient with Crohn's disease].Stanozolol-induced bland cholestasis.Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.Solving doubts about L-ornithine L-aspartate for overt hepatic encephalopathy: Whom and how to treat.Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients.Editorial: looking for patients at risk of cirrhosis in the general population-many needles in a haystack.New therapeutic perspectives in non-alcoholic steatohepatitis.[Influence of non-alcoholic fatty liver disease on cardiovascular disease].Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression.Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesityRe: Unsedated colonoscopy: an option for some but not for all[Alcoholic and non-alcoholic steatohepatitis: who is affected and what can we do for them?][Portal thrombosis: beyond liver cirrhosis]Deciphering the spectrum of low-grade hepatic encephalopathy in clinical practiceLactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy
P50
Q24658456-4841BE61-1C94-4C9E-A880-3F8B8D2684BFQ26784258-D93EA0FC-5759-4C8C-B058-43CF90647C82Q26864571-14B906BD-6DC4-4762-9617-06B5F463ADE0Q30376231-2B974AE0-CDE8-4258-AF27-BC65A1C65443Q31134437-4B7EF5D1-DD2A-4D7E-94BA-5DF5D657D67FQ33716191-6B71C5B5-69D5-474D-831B-6831CD508400Q34482159-8E202A82-8CEC-4B13-8D7B-F120755A2217Q35591160-7036E457-8921-4CB1-A778-26F53C37CF94Q37317444-20AC3C9F-0418-4864-91C9-DD3B5E3CEDE6Q38519928-CA940960-A7EF-4FB6-BE05-0C0952861ACDQ38645611-F0E273CC-3CC9-437B-A442-F7AABCF89B93Q38941218-F17B0CB7-5784-4629-AE2D-8CF2021B7F45Q38965567-83E3E8B6-942A-4B4F-893F-DADF84BC018EQ38966177-815C983E-8B9B-46AE-9236-0B196BD0B102Q39945625-A8AA0F49-F719-45F6-A69D-5AAC489A2D28Q40291661-E8B25084-212F-4C6A-90D6-AC5794347FEDQ40395597-B7721F98-2832-43DA-BC98-38A7844CFADAQ40416472-3BA91A3A-7AC3-4517-AA0E-DBAF4E8FC91AQ40567799-68246198-17E2-4E65-BEA1-8BEA3B8C34F4Q40677307-E0A2E04C-CBCB-43AD-8802-EDDCF8C773C2Q41269607-3961DB0D-325C-4E03-9526-BA0F6D6EB43AQ41459558-171CA784-234B-4760-A704-8846AE63260EQ41672917-CB241284-E42C-4448-9268-08EB72F7C220Q45389531-186F18A6-E8B7-4D07-B167-1D7899588A2FQ45748984-493AD1D8-38C8-463A-BB48-99293E7BE95AQ47183073-A8DDE82E-C3AE-4495-8A3C-BADEE4BB605AQ47547628-D5C626F0-82E1-4C81-819D-08FD01E5B16AQ48332597-9B3564C5-C497-41D9-8DE1-C77A6CA52B57Q49570178-5BE21BF4-633E-4B0E-9FF6-D5C14A9C401FQ50125118-FDB62FAA-9B4B-4F8F-97E3-2A3668810032Q50219936-855FC494-FCF6-4D9D-B8B2-CC7BD5DF9684Q50512072-87D9AAE3-D51C-4C41-9540-46A9C139B342Q51348775-0659A0B6-C820-4C24-9A88-F9CEE64396B2Q53427009-4ADDA01D-AE34-440D-8098-BD892DAA9FBBQ57795277-AB719FAF-83BC-4FBF-AAEE-FAD1FFB3E837Q84812157-2EAFB86A-60AE-405F-9B5C-107EBD5D0FD6Q85645874-5DB93113-39B9-46DC-9C1C-0E9BC3825034Q86098178-7E098B9E-419E-4A39-91DA-89B5B6C6D4F5Q87352429-64376CD2-2B54-4F95-8F4B-D2386B4028CBQ87843650-CD7FFE5F-629D-40C3-9115-E4B8334E532B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Javier Ampuero
@ast
Javier Ampuero
@en
Javier Ampuero
@es
Javier Ampuero
@nl
Javier Ampuero
@sl
type
label
Javier Ampuero
@ast
Javier Ampuero
@en
Javier Ampuero
@es
Javier Ampuero
@nl
Javier Ampuero
@sl
prefLabel
Javier Ampuero
@ast
Javier Ampuero
@en
Javier Ampuero
@es
Javier Ampuero
@nl
Javier Ampuero
@sl
P106
P1153
18633282000
57196059738
P21
P31
P496
0000-0002-8332-2122